**Background and importance** Most patients with intermediate-2 and high risk myelodysplastic syndrome (MDS) have a median age of 75 years and 25% are diagnosed after 80 years of age. Therefore, many may have great difficulty travelling to the hospital for the 7 day treatment for each cycle of 5-azacytidine.

**Aim and objectives** To analyse the experience and results of administration of 5-azacytidine in domiciliary care in daily clinical practice and to evaluate therapeutic adherence.

**Material and methods** A 4 year prospective observational study was conducted in 40 MDS patients with a median of age of 76 years, who had difficulty travelling to the day hospital to receive treatment with 5-azacytidine over 7 days. The drug was prepared in the hospital pharmacy service, using the water reconstitution method for refrigerated injections, and kept refrigerated (2–8°C), resulting in both chemically and physically stable solutions for 22 hours. Once inclusion of the patient in the study was confirmed by the haematologist, the prescribed treatment regimen was communicated to the pharmacy service and nurse to organise the medication regimen in domiciliary care. The variables considered in this study were: beginning of treatment with 5-azacytidine, treatment duration, level of satisfaction of patients, treatment adherence and side effects detected.

**Results** Forty MDS patients received treatment with 5-azacytidine in domiciliary care over a mean of 16 months of treatment: 75% of patients had great difficulty traveling to the day hospital because they required someone to accompany them and 35% did not have the supporting infrastructure. All (100%) patients were highly satisfied with the service, therapeutic adherence improved to 95% and side effects were detected in 15% of patients (neutropenia, anaemia and gastrointestinal reactions).

**Conclusion and relevance** Administration of 5-azacytidine in domiciliary care in older patients with MDS with difficulty travelling to the day hospital allowed greater support of these patients, improving the day hospital logistics, increasing patient satisfaction and adherence to treatment, and offering better quality healthcare.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
and trastuzumab. Infliximab biosimilar was introduced in September 2015 and rituximab and trastuzumab in August 2018. The results were analysed with Excel.

**Results** We identified 203 patients treated with infliximab, 16.2% for rheumatoid arthritis (RA) and its derivatives, 80.3% for inflammatory bowel disease (IBD) and 3.5% for other pathologies. A total of 54.7% of patients were treated with a biosimilar, 46.8% as the initial treatment and 7.9% as a switch. All (100%) switches were in patients treated for IBD.

Rituximab was used in 158 patients, 60.8% for different types of haematological cancer, 13.9% for RA, 5.1% for lupus and 20.2% for other diseases. A total of 51.3% of patients were treated with a biosimilar, 36.7% as the initial treatment and 14.6% as a switch. Most (65%) of the switches were found in haematological pathologies. Subcutaneous BRP were given to 29.7% of the total patients.

There were 77 patients treated with trastuzumab, 92.2% for breast cancer and 7.8% for gastric cancer. Of the 71 patients with breast cancer, 59.1% were treated with a biosimilar, 22.5% as the initial treatment and 36.6% as a switch. The remaining 40.9% were treated with subcutaneous BRP. In gastric cancer, 100% of patients were treated with a biosimilar, 66.7% from the beginning and 33.3% as a switch.

**Conclusion and relevance** The use of biosimilar drugs is more consolidated in new patients and switching is a slower dynamic. The arrival of new biosimilars in the coming years will increase their use. Some medical specialties are more likely to using biosimilar drugs. The presence of a subcutaneous BRP can make the use of biosimilar drugs more difficult as a switch or in new patients as physicians will prescribe a subcutaneous BRP instead of an intravenous biosimilar.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

https://ejhp.bmj.com/content/26/Suppl_1/A133.2

No conflict of interest.

4CPS-159 PRESCRIBING TRENDS OF ADALIMUMAB AND ETANERCEPT BIOSIMILAR DRUGS IN A THIRD LEVEL HOSPITAL

JM Vinuesa Hernando, R Gracia Piquer, FJ Campos Montellano, R Fresquet Molina, M Galindo Allueva, O Homa Oregia, A Fruitos Perez-Surio, MA Alcaerac Lopez*, T Salvador Gómez, M Gimeno Gracia. Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain

No conflict of interest.

4CPS-159 MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA AT A TERTIARY CARE TEACHING HOSPITAL

1M Alomar*, 2A Mayet, 4A Alsuwayehy, 3N Alkhayyat, 5D Almubhel, 1Clinical Pharmacist Specialist-Internal Medicine, Clinical Pharmacy, Riyadh, Saudi Arabia; 3King Saud University Medical City, Clinical Pharmacy, Riyadh, Saudi Arabia

10.1136/ejipharm-2020-eahpconf.260

**Background and importance** The implementation of community acquired pneumonia (CAP) guidelines has led to shortening the duration of antibiotic treatment, reducing costs and improving pneumonia related morbidity and mortality. Adherence to CAP guidelines is varied in multiple international studies. This study aimed to evaluate the rate of adherence to the 2007 guidelines from the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) for the diagnosis and treatment of CAP in hospitalised patients. We also wanted to identify patient related factors that may influence adherence to treatment guidelines at our tertiary care teaching hospital

**Aim and objectives** The aims of the study were to evaluate adherence to IDSA guidelines for the management of CAP.

**Material and methods** Patients admitted with CAP had their charts prospectively reviewed from 1 April to 31 July 2018. Patients were eligible to participate in the study if they were >18 years of age and the admitting diagnosis was CAP. Demographic data, comorbid conditions, smoking history, antibiotic culture and sensitivity, duration of antibiotic therapy, relevant laboratory data and diagnostic procedures were retrieved from the medical records. The proportion of patients who were treated according to CAP guidelines were recorded and compared with the most widely referenced guideline, IDSA/ATS for the treatment of CAP.

**Results** During the study period, 138 eligible patients were identified, 51.4% were women, mean age was 59.1±20 years and 49.3% had diabetes. Only 8% of patients received a